These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18546078)

  • 21. The role of inflammation in the pathophysiology of CF lung disease.
    Chmiel JF; Berger M; Konstan MW
    Clin Rev Allergy Immunol; 2002 Aug; 23(1):5-27. PubMed ID: 12162106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation and cystic fibrosis pulmonary disease.
    Kennedy MJ
    Pharmacotherapy; 2001 May; 21(5):593-603. PubMed ID: 11349748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of modulators of airways inflammation in patients with CF.
    Ren CL
    Clin Rev Allergy Immunol; 2002 Aug; 23(1):29-39. PubMed ID: 12162104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-inflammatory therapy in cystic fibrosis].
    Derelle J
    Arch Pediatr; 2003 Sep; 10 Suppl 2():370s-375s. PubMed ID: 14671937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging therapies in cystic fibrosis.
    Anderson P
    Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
    Perrem L; Ratjen F
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
    Caverly LJ; Zhao J; LiPuma JJ
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhaled medications in cystic fibrosis beyond antibiotics.
    Sepe A; Villella VR; Cimbalo C; Castaldo A; Nunziata F; Corcione A; Bona G; Maiuri L; Raia V
    Minerva Pediatr; 2019 Aug; 71(4):371-375. PubMed ID: 30761821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.
    Hsu D; Taylor P; Fletcher D; van Heeckeren R; Eastman J; van Heeckeren A; Davis P; Chmiel JF; Pearlman E; Bonfield TL
    Infect Immun; 2016 Sep; 84(9):2410-21. PubMed ID: 27271746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory therapies for cystic fibrosis.
    Thompson AB; Smits WL; Fick RB
    Semin Respir Infect; 1992 Sep; 7(3):218-26. PubMed ID: 1475545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation in cystic fibrosis: An update.
    Roesch EA; Nichols DP; Chmiel JF
    Pediatr Pulmonol; 2018 Nov; 53(S3):S30-S50. PubMed ID: 29999593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting airway inflammation in cystic fibrosis.
    McElvaney OJ; Wade P; Murphy M; Reeves EP; McElvaney NG
    Expert Rev Respir Med; 2019 Nov; 13(11):1041-1055. PubMed ID: 31530195
    [No Abstract]   [Full Text] [Related]  

  • 33. An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line.
    Sheikh Z; Bradbury P; Pozzoli M; Young PM; Ong HX; Traini D
    Eur J Pharm Biopharm; 2020 Nov; 156():121-130. PubMed ID: 32916267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line.
    Sheikh Z; Bradbury P; Reekie TA; Pozzoli M; Robinson PD; Kassiou M; Young PM; Ong HX; Traini D
    Eur J Pharmacol; 2021 Jul; 902():174098. PubMed ID: 33848541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.
    Scott LK; Toner R
    Lung; 2017 Aug; 195(4):397-401. PubMed ID: 28623538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
    Kunzelmann K; Mall M
    Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammation in cystic fibrosis--when and why? Friend or foe?
    Elston C; Geddes D
    Semin Respir Crit Care Med; 2007 Jun; 28(3):286-94. PubMed ID: 17562498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment strategies for cystic fibrosis: what's in the pipeline?
    Frerichs C; Smyth A
    Expert Opin Pharmacother; 2009 May; 10(7):1191-202. PubMed ID: 19405793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy.
    Boucher RC
    Annu Rev Med; 2007; 58():157-70. PubMed ID: 17217330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.